Recently, a large phase II trial including 160 histologically proven PTCL, with the exclusion of ALCL ALK positive, reported encouraging survival data, with a 5-year OS and PFS of 51% and 44%, using a dose dense CHOEP-14 induction therapy (CHOP-14 if age >60 years) and autologous SCT in responders[21]. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.